Master Clinical Study An open-label, multicentre, randomisedadaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild / moderate cases of COVID-19

The ANTICOV clinical trial aims to respond to the urgent need to identify treatments that can be used to treat mild and moderate cases of COVID-19 early and prevent spikes in hospitalizations that could overwhelm fragile and already overburdened health systems in Africa.

The ANTICOV clinical trial will provide evidence to lower the potential burden on the healthcare system, impacting transmission and preventing severe coronavirus associated disease progression in the targeted countries and across other countries. The main project outcome/indicator is the delivery of one to two treatment(s) that prevent patients from progressing to severe disease and that are adapted to LMIC settings. An early antiviral treatment could also potentially interrupt transmission.